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Discovery of Cancer Driver Long 
Noncoding RNAs across 1112 
Tumour Genomes: New Candidates 
and Distinguishing Features
Andrés Lanzós1,2,3, Joana Carlevaro-Fita1,2,3, Loris Mularoni4, Ferran Reverter1,2,3,  
Emilio Palumbo1,2,3, Roderic Guigó1,2,3 & Rory Johnson1,2,3,†
Long noncoding RNAs (lncRNAs) represent a vast unexplored genetic space that may hold missing 
drivers of tumourigenesis, but few such “driver lncRNAs” are known. Until now, they have been 
discovered through changes in expression, leading to problems in distinguishing between causative 
roles and passenger effects. We here present a different approach for driver lncRNA discovery using 
mutational patterns in tumour DNA. Our pipeline, ExInAtor, identifies genes with excess load of 
somatic single nucleotide variants (SNVs) across panels of tumour genomes. Heterogeneity in 
mutational signatures between cancer types and individuals is accounted for using a simple local 
trinucleotide background model, which yields high precision and low computational demands. We 
use ExInAtor to predict drivers from the GENCODE annotation across 1112 entire genomes from 23 
cancer types. Using a stratified approach, we identify 15 high-confidence candidates: 9 novel and 6 
known cancer-related genes, including MALAT1, NEAT1 and SAMMSON. Both known and novel driver 
lncRNAs are distinguished by elevated gene length, evolutionary conservation and expression. We have 
presented a first catalogue of mutated lncRNA genes driving cancer, which will grow and improve with 
the application of ExInAtor to future tumour genome projects.
Whole genome sequencing makes it possible to comprehensively discover the mutations, and the mutated genes, 
that are responsible for tumour formation. By sequencing pairs of normal and tumour genomes from large patient 
cohorts, projects such as the ICGC (International Cancer Genome Consortium) and TCGA (The Cancer Genome 
Atlas) aim to create definitive driver mutation catalogues for all common cancers1,2. Focussing on entire genomes, 
rather than just captured exomes, these studies hope to identify driver elements amongst the ~98% DNA that 
does not encode protein. These noncoding regions contain a wealth of regulatory sequences and non-coding 
RNAs whose role in cancer has been neglected until now3.
Amongst the most numerous, yet poorly understood of the latter are long noncoding RNAs (lncRNAs). These 
are long RNA transcripts that share many characteristics of mRNAs, with the key difference that they do not con-
tain any recognizable Open Reading Frame (ORF), and thus are unlikely to encode protein4. LncRNAs perform 
a diverse range of regulatory activities within both the nucleus and cytoplasm by interacting with protein com-
plexes or other nucleic acids5. While their expression tends to be lower than protein-coding mRNAs, lncRNAs are 
thought to be highly expressed in a subset of cells in a population6. The number of lncRNA genes in the human 
genome is still uncertain, but probably lies in the range 20,000–50,0007,8. This vast population of uncharacterized 
genes likely includes many with novel roles in cancer.
In recent years a small but growing number of lncRNA have been implicated in cancer progression through 
various mechanisms9. LincRNA-P21, a tumour suppressor, acts downstream of P53 by recruiting the repressor 
hnRNP-K to target genes10. Proto-oncogene lncRNAs include HOTAIR, upregulated in multiple cancers, which 
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recruits the repressive PRC2 chromatin regulatory complex to hundreds of genes11. Cancer-related lncRNA have 
features of functional genes, including sequence conservation, orthologues in other mammals, chromatin marks 
and regulated subcellular localisation4. Moreover they display typical characteristics of cancer drivers, including 
influence on cellular phenotypes of proliferation and apoptosis, and in clinical features such as patient survival 
and altered expression across tumour collections3,8,11.
The absence of whole-genome maps of somatic mutations has meant that searches for new cancer-related 
lncRNAs have relied on conventional transcriptomic approaches that reveal changes in their expression levels 
that accompany cancer. However such approaches are not capable of distinguishing passenger and driver effects, 
nor do they identify mutations in the mature lncRNA sequence that may drive tumourigenesis independent of 
upstream regulatory changes8,12,13. Two recent studies clearly demonstrate that somatic mutations, in these cases 
amplifications of entire loci, can drive tumour formation14,15. Nevertheless, we remain largely ignorant of the role 
that mutations in lncRNA genes play during the early stages of tumourigenesis.
The statistical analysis of somatic mutation patterns is a powerful means of identifying genes that drive early 
tumour formation. A number of methods have been developed to search for candidate driver genes whose open 
reading frames display non-random mutational patterns consistent with positive selection on the encoded pro-
tein. In essence, all methods search for statistical enrichment in some measure of mutational impact, compared 
to a background model that accounts as far as possible for biases inherent in mutational processes. For example, 
OncodriveFM16 employs predicted functional impact of mutations on encoded proteins, as inferred by a variety 
of methods, and using an empirical local background model. On the other hand, MutSigCV17 identifies genes 
with elevated mutational rates, incorporating a variety of known mutational covariates in order to estimate an 
accurate background model drawn from silent sites amongst selected neighbouring protein-coding sequences. 
Finally, ActiveDriver18 searches for genes with excess mutations falling in signaling sites, protein domains and 
regulatory motifs. While these approaches have discovered dozens of new cancer genes, their use of features spe-
cific to protein-coding genes to infer mutational biases, makes them inapplicable to lncRNA.
To date, the majority of driver discovery projects have been carried out using exome sequencing – the targeted 
capture and sequencing of approximately 2% of the genome encoding protein17. While successful for discovering 
protein-coding driver genes, exome sequencing ignores mutations occurring in the multitude of noncoding reg-
ulatory elements known to exist in the human genome19. Very recently, drops in the cost of sequencing have made 
plausible the sequencing of collections of entire tumour genomes1. Mutation maps from these genomes make it 
possible, for the first time, to search for non-coding driver elements.
In the present study, we describe and characterise a tool, called ExInAtor, for the discovery of driver lncRNA 
genes. ExInAtor identifies genes with excess of exonic mutations, compared to the expected local neutral rate esti-
mated from intronic and surrounding sequences. We present a comprehensive prediction of candidate lncRNAs 
across 1104 genomes from 23 cancer types. These candidates have a series of features consistent with their being 
genuine drivers.
Results
A method for discovering driver genes from cancer genomes. Our aim was to develop a method to 
identify tumour driver long noncoding RNAs (lncRNAs) using short nucleotide variant (SNV) mutations from 
cancer genome sequencing projects. We define SNVs, from now on, as somatic substitutions or indels of length 
1 nt. Only these mutations (representing the vast majority in this study, 97.7%) are used, due to the nature of 
ExInAtor’s statistical model (see Materials and Methods). The majority of GENCODE lncRNA annotations are 
spliced (21,523/23,898 = 90.0% of transcripts), and we assume throughout that their functional sequence resides 
in exonic regions that are incorporated into the mature transcript20. Intronic sequence is removed during splic-
ing and hence is not directly relevant to their function. Consequently, we hypothesised that driver lncRNAs will 
display an excess of somatic mutations in exons compared to the local background mutational rate, estimated by 
their introns and flanking genomic regions – henceforth referred to as “background regions”. This approach is 
conservative, given that background regions are likely to include functional regulatory elements that may them-
selves carry driver mutations.
We implemented this approach in a computational pipeline called ExInAtor (Fig. 1 and Supplementary Fig. S1). 
ExInAtor requires two principal inputs: an annotation of lncRNA genes and a catalogue of tumour mutations. 
At its heart, ExInAtor employs a parametric statistical test to identify genes that present a significantly elevated 
exonic mutation rate compared to local background regions. The latter are comprised of intronic and flanking 
genomic sequence. We took care to account for a key confounding factor: the unique mixture of mutational signa-
tures that characterises every individual tumour, and every tumour type21. Such signatures can be described as a 
probability for every nucleotide to mutate to every other, conditioned on the identity of flanking positions – sum-
marised in a matrix of 96 trinucleotide substitution frequencies21. In other words, mutation rates are dependent 
on nucleotide composition. The mutational signature must be taken into account when comparing mutational 
loads of exons to surrounding regions, because they tend to have marked differences in nucleotide composition – 
both for protein-coding genes and lncRNAs22.
ExInAtor employs a subsampling approach to balance the trinucleotide content of exons and background 
regions, thereby accounting for mutational signatures (Fig. 1A, Supplementary Fig. S1). Exonic regions of each 
gene are defined as the projection of all exons from the union of its transcripts. Next, the background region 
is defined as all non-exonic nucleotides within the gene, in addition to upstream and downstream windows of 
defined length. Within these exonic and background regions, the frequencies of trinucleotides are calculated. 
Then, nucleotides are randomly sampled (without replacement) from the background region, until the maximum 
possible amount of sequence with identical trinucleotide composition has been collected. Now, the number of 
SNVs overlapping exons, M, and those overlapping remaining background nucleotides, m, are compared using 
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a contingency-table analysis and statistical significance is calculated according to hypergeometric distribution 
(Fig. 1B) (see Materials and Methods for more details).
We prepared a carefully-filtered lncRNA annotation, to avoid several potential sources of false positive predic-
tions. We were particularly concerned by two potential confounding factors: first, misinterpretation of mutations 
that may affect protein-coding regions overlapping the same DNA as lncRNA exons; and second, the presence of 
mis-classified protein-coding transcripts among the GENCODE annotation4. Thus, we removed genes of uncer-
tain protein-coding potential, as judged by computational protein-coding potential classifiers (see Materials 
and Methods). We also removed any lncRNA genes, such as cis-antisense and intronic lncRNAs, that overlap 
annotated protein-coding genes. In this way we narrowed the set of GENCODE v19 lncRNA genes from 13,870 
to 5,887 intergenic, confidently-noncoding lncRNAs (Table 1). To this set we added back 27 cancer-related, 
GENCODE v19 lncRNAs from the literature (see below).
One advantage of ExInAtor is its indifference to genes’ biotype. This arises from its lack of reliance on meas-
ures of functional impact16, meaning that it can equally be used on lncRNAs or protein-coding genes. Indeed, 
similar approaches have been used to discover coding driver genes in the past23. We took advantage of this to 
assess its ability to discover known protein-coding driver genes from the Cancer Gene Census24 amongst the 
GENCODE annotation. This provided us with a useful independent validation of ExInAtor’s precision, of par-
ticular value given the low number of known driver lncRNAs at present.
Datasets of somatic mutations in cancer genomes. To search for lncRNA driver genes, we took 
advantage of the two largest available sources of cancer genome mutations: one collected by the Cancer Genome 
Project at the Sanger Institute, hereafter named “Alexandrov”21, and the other from The Cancer Genome Atlas 
(TCGA)1 (Table 2). These data were aggressively filtered to remove potential artefacts arising from germline 
mutations (see Materials and Methods). The Alexandrov dataset comprises 9 cancers with between 15 and 119 
individuals and 10,436 and 2,796,863 mutations each. The TCGA dataset consists of 14 cancers with between 
15 and 96 individuals and 21,113 to 4,680,653 mutations each. Of note is the large spread in sample sizes and 
mutation rates across tumour types. Taking all cancers together, we observed an excess of mutations in lncRNAs 
Figure 1. Outline of the ExInAtor method. (A) The steps of gene definition, subsampling and analysis 
performed to quantify exonic and background mutations. Sampling is performed in such a way that, at the 
end, the trinucleotide frequency of the background region is identical to the exonic region. (B) The number of 
mutations in background and exonic regions is compared by a contingency table analysis.
Element
LncRNA Protein coding
CRL Non-CRL Total CGC Not CGC Total
Genes 45 5,869 5,914 545 19,769 20,314
Transcripts 297 9,086 9,383 3,239 78,463 81,702
Exons 1,259 27,025 28,284 35,902 702,974 738,876
Merged Exons 267 19,153 19,420 9,326 218,186 227,512
Table 1.  Filtered gene sets. Cancer Related LncRNAs (CRL) and Cancer Gene Census (CGC) are manually-
curated, true positive sets of lncRNA and protein-coding genes, respectively.
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compared to protein-coding genes, and in background over exons, suggesting a general selective pressure against 
disruptive mutations in both gene classes (Supplementary Fig. S2).
The landscape of driver lncRNAs across 23 tumour types. To comprehensively discover candidate 
lncRNA drivers, ExInAtor was run on the 23 tumour types described above. We adopted some analysis strategies 
to account for the relatively shallow nature of the data and our consequently weak statistical power to find driver 
genes. First, in order to discover both cancer-specific and ubiquitous driver genes, ExInAtor was run on each 
dataset in distinct configurations: (1) grouping samples by tumour type (“Tumour Specific”), (2) pooling together 
the entire set of tumours within each of the two projects (“Pancancer”) and (3) pooling data across both projects 
(“Superpancancer”).
Second, we used sample stratification to boost sensitivity. This approach is commonly used when statistical 
power is reduced by multiple hypothesis testing25,26. LncRNA genes were divided into two groups of different 
sizes, and each was treated independently during multiple hypothesis correction. This reduces the burden on 
resulting false discovery rate estimates. As a reference set, we curated 45 experimentally-validated cancer-related 
lncRNAs from the scientific literature, henceforth “Cancer-Related LncRNAs” (CRLs) (Supplementary File S1). 
All CRL genes belong to GENCODE v19 annotation. Remaining filtered lncRNAs are referred to as “Non-CRL” 
(Supplementary File S2). Summary statistics of the gene sets used are shown in Table 1.
At a Q value (false discovery rate) cutoff of 0.1, we discovered a total of 15 lncRNAs (6 and 9 from CRL and 
non-CRL, respectively) (Fig. 2A) (Supplementary Files S3 and S4) and 24 protein-coding genes (Supplementary 
File S5). Relaxing the cutoff to Q < 0.2, we discover 10 and 27 CRL and non-CRL lncRNAs, respectively. 
Henceforth we refer to these as driver genes, and a Q-value threshold of 0.1 is assumed unless stated other-
wise. ExInAtor predicted a total of five lncRNA driver genes in Alexandrov tumours, nine in TCGA and two in 
Superpancancer (one of them already detected in Pancancer TCGA). The greatest numbers of drivers predicted 
in individual tumours were three apiece in Breast and Kidney Chromophore (Fig. 2D).
Several findings suggest that false positive prediction rates are low. Reported P values closely follow the 
expected null distribution for the majority of genes (a full set of Quantile-quantile (QQ) plots can be found in 
Supplementary Fig. S3). Furthermore, while a number of tumour types display a small number of putative driver 
lncRNAs that strongly deviate from the null expectation (exemplified by Breast cancer sample in Fig. 2B), other 
samples yield no candidates at all (eg Liver cancer, Fig. 2C). In general, inspection of QQ plots shows a tendency 
for deflation of P values (Supplementary Fig. S3). To further test false discovery rates, we reran these analyses 
on tumour data that had been randomised using two different methods (see Materials and Methods for details). 
ExInAtor predicted no lncRNA drivers in either dataset (grey dots in Fig. 2B and C and Supplementary Fig. S3).
Dataset Cancer Mutations Genomes
Alexandrov Breast 655,823 119
Alexandrov CLL 51,377 28
Alexandrov Liver 867,080 88
Alexandrov Lung_adeno 1,520,078 24
Alexandrov Lymphoma_B-cell 126,581 24
Alexandrov Medulloblastoma 123,642 100
Alexandrov Pancreas 110,944 15
Alexandrov Pilocytic_astrocytoma 10,436 101
Alexandrov Stad 2,796,863 100
Alexandrov Pancancer 6,259,996 607
TCGA BLCA 385,128 21
TCGA BRCA 620,238 96
TCGA CRC 4,680,653 42
TCGA GBM 180,896 27
TCGA HNSC 295,709 27
TCGA KICH 24,508 15
TCGA KIRC 131,828 29
TCGA LGG 35,474 18
TCGA LUAD 1,237,722 46
TCGA LUSC 1,626,973 45
TCGA PRAD 21,113 20
TCGA SKCM 3,538,750 38
TCGA THCA 37,882 34
TCGA UCEC 2,268,210 47
TCGA Pancancer 14,841,279 505
Both Superpancancer 20,837,263 1112
Table 2.  Cancer datasets used in this study.
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In order to rule out the possibility that our candidates are false candidates due to effects of elevated local 
mutation rates, or gene lengths, we performed two additional simulations. For these analysis we selected the 
Breast collection, as it has the highest number of non-CRL predictions (3). In the first simulation, we shuffled 
the lncRNA genes 100 times within the whole genome, not altering exon-intron structure, and keeping real 
mutation positions. The real number of candidates is greater than 97% of simulations, finding an average of 
0.52 candidates per iteration which implies a false discovery rate of ~0.17, consistent with our cutoff of FDR 0.1 
(Supplementary Fig. S4). In the second simulation, we examined whether predicted targets could be false posi-
tives due to locally elevated mutational rates. We constructed an annotation of artificial “intronic” genes, where 
the exons were replaced by equally-sized, randomly-selected fragments of introns from the same gene. These 
genes were used as the input for ExInAtor and run (with same settings as for real data) on Breast samples. Zero 
candidate drivers were predicted (Supplementary Fig. S5).
Together these data point to a rather conservative statistical model, with low false positive predictions, which 
may discard some bona fide drivers. A comprehensive set of predictions across all analyses can be found in 
Supplementary File S6.
ExInAtor identifies known and novel lncRNA driver genes. ExInAtor’s sensitivity is demonstrated 
by its identification of altogether six CRL genes. These are: MALAT1, NEAT1, PCA3, BCAR4, lncRNA-ATB 
(CTD− 2314B22.3) and the recently-discovered melanoma driver SAMMSON (RP11− 460N16.1) (Table 3). 
The latter was detected in stomach adenocarcinoma, and we found that it is also present in stomach RNAseq 
(Supplementary Fig. S6). The majority of candidates were found in tumour-specific analysis (Fig. 3A). 
Nevertheless, two CRL lncRNAs, NEAT1 and MALAT1, were identified in Pancancer analysis, consistent with a 
general role in tumourigenesis: both are long, unspliced and nuclear-retained lncRNAs with demonstrated roles 
across a range of cancer types9. It’s worth mentioning that neither of these genes was identified in the positional 
Figure 2. The landscape of driver lncRNAs across 23 tumour types. (A) The numbers and proportion of 
literature-reported cancer-related long noncoding RNAs (CRL) and non-CRL candidates identified in this 
study. Q value is equivalent to false discovery rate (FDR). (B) A Quantile-Quantile (QQ) plot showing the 
performance of ExInAtor on Breast cancer mutations. Each point represents one gene. Note the deviation of real 
P values from the theoretical distribution in a small tail of cases. Simulated data was created by randomising 
mutations while maintaining trinucleotide context. (C) As for B, for Liver cancer. Note the lack of candidates in 
this dataset. (D) The number of driver genes discovered at a Q cutoff of 0.1 across the Alexandrov and TCGA 
collections. Cancer Gene Census (CGC) are true positive, known protein-coding cancer driver genes.
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shuffling of Breast data described above, suggesting that these genes are not false positives due to their length. As 
shown in Fig. 3B, the NEAT1 exon region experiences an elevated mutation rate across cancers, when compared 
to its flanking background regions. NEAT1 was identified in a recent study of liver cancer genomes, and as the 
authors pointed out, it cannot be ruled out that it is identified through increased local mutation rate27.
One important potential source of false positive signal in this study could be elevated mutational rates in 
DNA regulatory elements, such as enhancers, which happen to overlap the exon of a lncRNA annotation. Such 
cases would be expected to produce driver lncRNAs, where all mutations are concentrated in a single exon. This 
would be indistinguishable from bona fide driver lncRNAs that have an important functional domain located in 
a single exon. To investigate this further, we inspected the exon-level mutational density of all candidate lncRNAs 
(Supplementary Fig. S7). Intriguingly, we find at least two cases where mutations are elevated across multiple 
exons, but not intervening introns (Fig. 3C and D). Altogether of 13 multi-exonic candidate lncRNAs, five have 
mutations in more than one exon. This supports the interpretation that, for these cases at least, mutations cause 
gain- or loss-of-function in mature lncRNA transcripts, and not through disruption of a DNA-encoded element.
Amongst the novel candidate driver genes were a number of intriguing cases with various characteristics of 
functionality, none of which have been described in the scientific literature. In Fig. 3F we highlight one case from 
the wider Q < 0.2 candidate set (see Supplementary File S6), RP11-820L6.1, whose promoter is characterised by 
canonical histone modifications, obvious evolutionary conservation and the recruitment of transcription factors. 
Most notably, the master tumour suppressor transcription factor and regulator of several cancer lncRNAs, P53, 
is bound within the first intron28.
We further sought to establish the degree of overlap between ExInAtor-predicted driver genes and candidates 
predicted by transcriptomic analyses. Two previous studies to identify cancer-related lncRNAs have searched 
for differentially-expressed transcripts in cancer transcriptome data from microarrays and RNA sequencing8,12. 
From each study we extracted those transcripts that overlap the filtered geneset used here, retrieving a total of 80 
and 186 genes from the Du et al. and Iyer et al. (“MiTranscriptome”) studies, respectively (Supplementary Files 
S7 and S8)8,12. Three genes are identified by both ExInAtor and MiTranscriptome (PCA3, NEAT1 and MALAT1) 
(P = 0.0026, Chi-square with Yates’ correction test) and another with Du et al. (PCA3) (P = 0.5, Chi-square with 
Yates’ correction test) (Supplementary Fig. S8). It should be noted that all these genes belong to the CRL set. 
MiTranscriptome and Du share 11 genes (P < = 0.0001, Chi-square with Yates’ correction test). This surprising 
discordance of driver gene prediction between studies, in addition to their lack of overall intersection with the 
published CRL set, suggests that (1) these large-scale predictions have considerable false negative rates, and (2) 
that available catalogues of cancer-related lncRNAs, represented by the CRL set, are incomplete.
We searched for independent evidence of cancer roles for ExInAtor-predicted candidates. Importantly, we 
separately considered (1) the entire set of candidates, including known CRL genes, and (2), the novel ExInAtor 
candidates alone. This ensures that findings are not biased by the inclusion of experimentally-verified CRL drivers 
amongst candidate gene sets. We first tested the frequency with which candidates are affected by copy number 
variants (CNVs) across matched cancers29. We found that all candidates, and novel candidates alone, both display 
a trend to have elevated rates of copy number variation (Fig. 3E). We also investigated whether candidates are 
more proximal to germline cancer mutations29. Once more, we observe a trend for candidates to be more likely to 
Cancer Gene Name Gene ID Ex mut Ex len Intr mut Intr len Pval Qval Ex mut rate Intr mut rate Ratio
Breast AP000469.2 ENSG00000224832 9 238824 2 1176908 4.38E-06 5.05E-03 3.77E-02 1.70E-03 22.2
Stad PCA3 ENSG00000225937 10 392190 20 2702680 2.86E-03 5.49E-02 2.55E-02 7.40E-03 3.4
KICH RP11-308N19.1 ENSG00000234323 1 26384 1 2437289 2.13E-02 6.39E-02 3.79E-02 4.10E-04 92.4
Stad SAMMSON ENSG00000240405 5 208795 1 697899 3.14E-03 5.49E-02 2.39E-02 1.43E-03 16.7
GBM lncRNA-ATB ENSG00000244306 4 314168 4 1347296 4.68E-02 9.36E-02 1.27E-02 2.97E-03 4.3
Super_Pc NEAT1 ENSG00000245532 163 25316741 16 5559984 4.98E-04 2.19E-02 6.44E-03 2.88E-03 2.2
Pc_TCGA NEAT1 ENSG00000245532 96 11497239 7 2524993 9.28E-04 4.08E-02 8.35E-03 2.77E-03 3.0
PRAD RP11-455B3.1 ENSG00000248202 7 16573 1 380379 1.70E-09 1.19E-08 4.22E-01 2.63E-03 160.7
KICH RP11-332J15.1 ENSG00000249734 3 8277 15 314985 1.03E-02 6.39E-02 3.62E-01 4.76E-02 7.6
Breast RP11-707A18.1 ENSG00000250125 6 485395 9 6908893 2.38E-04 9.16E-02 1.24E-02 1.30E-03 9.5
KICH RP11-6C14.1 ENSG00000250488 1 5369 1 687929 1.54E-02 6.39E-02 1.86E-01 1.45E-03 128.1
Super_Pc MALAT1 ENSG00000251562 83 9683213 40 7768392 4.45E-03 9.79E-02 8.57E-03 5.15E-03 1.7
Breast RP11-1101K5.1 ENSG00000253434 6 165285 19 4878981 1.28E-04 7.38E-02 3.63E-02 3.89E-03 9.3
HNSC RP11-354A14.1 ENSG00000254689 3 12579 4 697784 1.84E-04 8.14E-02 2.38E-01 5.73E-03 41.6
BRCA RP11-189E14.4 ENSG00000261623 9 352599 1 1252991 9.53E-06 9.25E-03 2.55E-02 7.98E-04 32.0
SKCM BCAR4 ENSG00000262117 6 50458 8 533056 6.81E-04 2.11E-02 1.19E-01 1.50E-02 7.9
Table 3.  List of predicted lncRNA drivers at Q < 0.1. Known cancer genes from CRL are marked in bold 
face. “Pc” - PanCancer. Ex mut: Number of exonic mutations; Ex len: total exonic length of gene (bp); Intr mut: 
Number of background mutations; Intr length: background region length for gene (bp); Pval: uncorrected 
P-value; Qval: Q-value, equivalent to False Discovery Rate; Ex mut rate: Exonic mutation rate (mutations per 
kb); Intr mut rate: Background mutation rate (mutations per kb); Ratio: Ratio of mutation ratio in exonic and 
background regions; Super_pc: Super pancancer – all cancers combined. 
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Figure 3. LncRNA cancer driver genes predicted by ExInAtor across cancer genomes. (A) All driver lncRNAs 
(Q ≤ 0.1) and the tumour type in which they are identified. Gene names in blue indicate those belonging to 
CRL. (B) A mutation density plot for NEAT1 in all cancers, plotting the SNVs per kilobase as a function of gene 
regions. Grey represent background regions, while colours represent the mutational contribution of each cancer 
type to the single exon. The x-axis represents position, in bp, with respect to the start of the background region, 
defined here to be at 10 kb upstream of the gene’s annotated TSS. (C) The Breast mutation profile of RP11-
1101K5.1, a gene with mutations in four exons. Rectangles depict mutational density of exons (blue) and introns 
(grey). The gene structure is indicated below, where wider portions represent exons, separated by narrower 
introns. (D) The Breast mutation frequency in BCAR4. (E) Percentage of genes and candidates in CNV regions 
and proximal to cancer-related germline SNPs. Numbers above bars indicate the absolute numbers of genes 
represented by each percentage. Statistical significance in each case was estimated using Fisher’s Exact test. (F) 
An example of an ExInAtor-predicted novel candidate gene, RP11-820L6.1. Note the presence of promoter-like 
histone marks (red, ChromHMM track), evolutionary conservation (PhastCons Primate conservation), and 
cancer SNVs around the gene TSS, as well as a proximal P53 binding site (“P53_merged”).
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be proximally located to such mutations than expected by chance. Although the small numbers involved do not 
generally reach statistical significance, these findings are additional evidence that ExInAtor predictions, either 
including or excluding known cancer-related lncRNAs, are involved in tumour progression.
ExInAtor identifies known protein-coding cancer genes. Although ExInAtor was designed with 
lncRNAs in mind, it makes no use of functional impact predictions and hence is agnostic to the protein-coding 
potential of the genes it analyses. We took advantage of this versatility to further test ExInAtor’s precision, 
by comparing predictions to the gold-standard catalogue of the Cancer Gene Census (CGC)24. CGC is a 
manually-curated and regularly-updated annotation of genes whose somatic mutations have been associated 
with cancer. CGC genes represent a subset of 545 genes (Supplementary File S9) (2.7%) of the entire GENCODE 
set of 20,314 studied here (Supplementary File S10) (Table 1).
We ran ExInAtor using protein-coding gene annotations, without stratification. Altogether, a total of 24 
protein-coding drivers were identified at a false discovery rate cutoff of Q < 0.1. Of these, 9 (38%) are CGC 
genes (indicated in red, Fig. 4A). This represents enrichment of 14-fold over random expectation (P < = 0.0001, 
Chi-square with Yates’ correction test). The most significantly enriched gene in this analysis is TP53, the most 
frequently mutated across cancers and identified in previous exome sequencing projects30. TP53 exons display an 
obvious and consistent enrichment of somatic mutations in both datasets, clustered in exons 4 and 7–11 (Fig. 4D). 
This TP53 signal is observed in both Pancancer and multiple individual cancer types.
Several of the 15 non-CGC genes identified have evidence for cancer roles: ANKRD18A in lung cancer31, 
DDX3X and PBRM1 in various cancers32, HPSE2 in thyroid carcinoma33, MYO5B in gastric cancer34. These find-
ings suggest that ExInAtor precision may be better than implied by the analysis of CGC genes alone.
We examined the performance of ExInAtor, in terms of the percent of predicted genes that belong to CGC, at 
a series of Q value thresholds (Fig. 4B) (Supplementary File S11). Shown are separate analyses for all cancer types 
(expressed as mean prediction per cancer), and various pancancer combinations. These show that, although the 
number of predicted genes are low, they tend to have far higher rate than that 2.7% expected by random chance, 
even at a Q value threshold of 0.1.
In summary, ExInAtor performs well in identifying known cancer related genes at high precision from a 
protein-coding training set ~10 times larger than CRL lncRNAs.
ExInAtor is competitive with tools designed for protein-coding genes. Next we compared 
ExInAtor to a series of well-known pipelines for identification of protein-coding drivers: MutSig17, OncodriveFM16 
and OncodriveClust35. In side-by-side analyses on identical Alexandrov Pancancer data, we found that ExInAtor 
has low sensitivity (ie makes few predictions), but has excellent precision. In fact, its predictions contain a higher 
percentage of CGC genes than the other methods (Fig. 4C and Supplementary Fig. S9). For example, at a cutoff 
of Q < 0.1, ExInAtor predicts 3 genes (of which 2 are known drivers), compared to 4 known drivers out of 39 for 
MutSig, 11 known drivers out of 104 for OncoDriveClust and 59 known drivers out of 589 for OncodriveFM 
(Fig. 4C). Furthermore, comparing the top 30 candidates detected at several cutoffs (Supplementary Fig. S10), the 
majority of genes detected by ExInAtor are also detected by at least one other method.
We also compared the four programs’ performance on real and simulated Pancancer data, displayed as Q-Q 
plots in Supplementary Fig. S11. Again, ExInAtor performs relatively well: its predictions on true data mirror 
the expected distribution quite well, and true P values are smaller than for simulated data. ExInAtor predictions 
appear to be conservative, having a tendency for moderately deflated P values. In contrast, other methods tend to 
perform worse, being either strongly deflated (MutSig), inflated (OncodriveFM) or predicting less in true than 
randomised data (OncodriveClust). In summary, despite not employing any information from functional impact 
of mutations on protein-coding sequence to inform its predictions, ExInAtor is surprisingly competitive with 
existing methods in the identification of coding driver genes. In particular, its predictions have low sensitivity 
(possibly many false negatives) but high precision (a high fraction of true positives). This lends weight to the 
accuracy of ExInAtor’s lncRNA predictions.
LncRNAs are predicted as drivers at higher rates compared to coding genes. We were inter-
ested in the overall rates of prediction of lncRNAs and protein-coding genes, as well as their apparent 
tumour-specificity. Known driver genes are highly variable with respect to their tumour-type specificity. TP53 
mutations are found across a wide range of cancers, while other drivers are only mutated in single tumour 
types30,32. In this analysis, we detected no lncRNAs in more than one tumour (Supplementary Fig. S12). In con-
trast, two coding genes were discovered in two independent cancer types, while TP53 was identified in no less 
than 9. Interestingly, a higher fraction of lncRNAs was predicted as driver genes than protein coding: 0.25% and 
0.11%, respectively. These figures are likely to be strongly influenced by both the low sensitivity of ExInAtor 
discussed above and by the sparse data. In future, many more genes are likely to be identified in multiple cancers 
when deeper data is available. Nevertheless these findings suggest that lncRNA are mutated in cancer at a rate 
similar to, or higher than protein-coding genes.
Novel and known driver lncRNAs share distinctive features of functionality. Returning to the 
driver lncRNAs identified by ExInAtor, we next asked whether any features distinguish these from other lncR-
NAs. Previous studies of lncRNA have used features such as evolutionary conservation and expression as proxies 
for functionality36,37. Furthermore, previous research on protein-coding cancer genes showed that their genes and 
their processed transcripts tend to be longer than average38.
We compiled a series of features and, for each one, asked to what extent it differs between the CRL genes 
and all other lncRNAs. The full set of results, plotted by magnitude of difference and statistical significance, are 
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shown in Fig. 5A. It is clear that CRL genes are distinguished by a diverse range of features. They are transcribed 
from longer genes, and have longer mature transcripts (“exonic length”). They are under stronger evolutionary 
constraint: their promoters and exons are more evolutionarily conserved across a range of evolutionary distances. 
Their steady state RNA levels are higher and more variable across human tissues. Finally, they are also more likely 
Figure 4. ExInAtor discovers known protein-coding drivers at high precision. (A) The –log10 Q-values of all 
candidates at Q ≤ 0.1 cutoff in the Alexandrov and TCGA datasets. Gene names in red indicate known drivers 
belonging to the Cancer Gene Census (CGC). (B) The precision of ExInAtor predictions was estimated as the 
percent of predicted driver genes that also belong to CGC. Bars are coloured by the Q-value cutoff used, and 
the fraction of all known genes belonging to CGC is shown in blue as a reference. “Mean” displays the average 
overlap across all individual cancer types. The numbers above each bar indicate the total number of predicted 
driver genes at that cutoff. For example, in “Superpancer”, a total of three candidates are identified at a cutoff of 
0.1, of which two (66%) belong to CGC. (C) Comparison of the performance of ExInAtor to other methods for 
protein-coding driver gene discovery, using the Alexandrov Pancancer dataset. Plot description as for Panel B. 
(D) The mutational profile of the TP53 tumour suppressor gene across all cancers. x axis indicates the position 
within the gene, y axis shows the mutation frequency.
www.nature.com/scientificreports/
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Figure 5. Features distinguishing cancer lncRNAs are also found in ExInAtor candidates. (A) Identification 
of cancer lncRNA features by comparing literature-curated Cancer Related LncRNA (CRL) genes to others. 
Dots represent 16 features that were compared in CRL and non-CRL genes. y axis shows the log2 fold difference 
of CRL vs non-CRL means for the values of the given feature. x axis represents the P value obtained from the 
statistical test applied when comparing CRL and non-CRL. Features are coloured depending on whether they 
are discrete features, analysed by Fisher Exact test, or continuous features analysed by Wilcoxon test. (B) Cancer 
lncRNA features in ExInAtor-predicted driver genes. Shown are cumulative distributions for seven selected 
features. Dashed vertical lines indicate the mean value of each group. Genes are grouped by: literature-reported 
cancer CRL lncRNAs, all ExInAtor candidates (both CRL and not) (“All candidates”), only novel ExInAtor 
candidates that are not included in CRL (“novel candidates”), and non-CRL non-candidates, being all other 
GENCODE lincRNAs. Candidates here were defined at a Q ≤ 0.2. Groups significantly different from the latter 
at a threshold of P = 0.05 (Wilcoxon test) are represented by a thick line.
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to be proximal to a binding site of the P53 tumour suppressor. In contrast, there is no difference in genic or exonic 
GC content between CRLs and other genes.
Having established a series of cancer lncRNA-specific features, we asked whether these features are also pres-
ent in ExInAtor candidate genes. We were particularly interested in whether novel candidates (ie non-CRL) 
share these characteristics, since this would represent an independent test for the value of ExInAtor predictions. 
Therefore we compared the features of three gene groups: CRL lncRNAs, all ExInAtor candidate genes, and novel 
ExInAtor candidates alone. These groups were compared to the null set of genes, represented by the entire set of 
remaining Gencode lincRNAs (“All other genes”).
In Fig. 5B are shown the results across seven selected features. ExInAtor candidates, in common with CRL, 
have longer genes and transcripts than lincRNAs in general (P = 4E-8, P = 6E-4, respectively, Wilcoxon test). 
Surprisingly, and in contrast to CRL genes, ExInAtor candidates have significantly lower GC content (P = 7E-3), 
and higher repetitive sequence content (P = 0.03). Finally, for features of evolutionary conservation of both pro-
moter and exon, in addition to steady-state RNA levels, we find that novel candidates display a similar trend 
as CRL genes, although these do not reach statistical significance (P > 0.05). In summary, and pending future 
replication with larger gene sets, it appears that novel ExInAtor predicted cancer genes share a number of distin-
guishing features with known cancer lncRNAs, consistent with being bona fide driver genes.
Discussion
Here we have presented ExInAtor, to our knowledge the first method specifically designed to identify cancer 
driver lncRNAs from tumour genome cohorts. ExInAtor aims to address the unique opportunity of compre-
hensively discovering cancer driver lncRNAs within and across tumour types using mutation data generated by 
projects such as TCGA and ICGC.
ExInAtor is the first approach dedicated to identifying driver lncRNAs. Due to their explicit use of 
protein-coding information, most existing tools are inappropriate for this task16–18. The most similar existing 
tool is probably InVEx23, which uses within-sample empirical distributions to identify protein-coding drivers. 
However it differs in several key ways from ExInAtor: InVEx utilises protein-based mutational impact scores to 
judge impact of mutated positions, while ExInAtor uses simple mutational burden; InVEx relies on randomi-
sation, while ExInAtor utilizes the hypergeometric distribution for increased processing speed; and ExInAtor 
uses a larger, more flexible background region encompassing both flanking and intronic regions (InVEx utilises 
introns and UTRs only). In particular, the requirement for mutational impact scores would appear to make InVEx 
unsuited to analysis of the type presented here.
We have presented the results of scans across the two most substantial tumour genome sequencing cohorts 
presently available, the Alexandrov and TCGA datasets, altogether comprising more than 1000 genomes from 
23 cancer types. In addition to successfully retrieving at nine known protein-coding drivers (38% of total predic-
tions) and six published cancer-related lncRNAs (40% of predictions), we identify for the first time a total of nine 
novel lncRNA driver genes at low false positive rates (0.1 FDR). These novel candidates share with known cancer 
lncRNAs a series of features including evolutionary conservation, normal tissue expression and gene length. They 
also tend to be proximal to germline cancer SNPs and have increased probability of lying in CNV regions, lending 
weight to their association with tumourigenesis. Together these observations support the idea that ExInAtor pre-
dicts bona fide driver lncRNAs. The true test of these predictions must await experimental validation in cell lines 
and animal models, where the tumorigenic effect of the observed tumour SNPs can be tested in a controlled way.
The distinguishing features of cancer-related lncRNAs are reminiscent of similar findings for protein coding 
genes38. Evolutionary conservation and high steady-state RNA levels are generally interpreted in this context as 
evidence for functionality of lncRNAs36,37. The significance of other features is less clear, and we should be careful 
to consider possible non-biological factors. In the case of gene length, it is likely that ExInAtor has greater statisti-
cal power for longer genes, possibly explaining the significantly elevated lengths of known and novel candidates. 
Furthermore, it is likely that the annotated length of lncRNAs is correlated with their expression, since higher 
expressed genes have more supporting ESTs and cDNAs, and hence are more complete.
Other observations were unexpected: the exons of novel candidate drivers have elevated repetitive content 
and reduced GC content. Furthermore, and in contrast to the above, these features are not shared with known 
CRL driver genes. It is unclear whether this reflects technical artefacts of the analysis, or a genuine biological 
insight. We can think of no bias in ExInAtor, or the cancer mutation datasets, that may favour gene models with 
these properties, although it is entirely feasible. On the other hand, transposable elements have been linked to 
both cancer39,40 and lncRNA functionality41. It is attractive to hypothesise that repeat-rich lncRNAs play roles in 
tumourigenesis and are preferentially mutated during this process. Further study will be required to establish the 
significance of these findings.
Previous driver gene predictions have been prone to false positive predictions arising from heterogeneous 
mutational rates, most notably those correlating with low gene expression level and late replication timing17. 
Although the use of local background mutation rates in ExInAtor would be expected to mitigate this, we con-
sidered whether such processes could have introduced error in this study. Both replication timing (earlier than 
average, Supplementary Fig. S14) and expression (higher than average, Fig. 5B) of candidate driver lncRNAs 
are opposite to that expected if they were false positives. Furthermore, the high precision of protein-coding 
predictions with respect to the Cancer Gene Census, the favourable performance compared to well-established 
methods, and the lack of predictions in locally-shuffled data (that presumably maintains replication-dependent 
mutational biases) are also inconsistent with such an effect. Finally, of the 24 ExInAtor protein-coding candidates, 
none are amongst the problematic false positive genes mentioned in the Lawrence et al. study17. Nevertheless it 
will be important to remain vigilant for these and other sources of error in future lncRNA driver discovery efforts.
At present, our understanding of how lncRNA function is encoded in sequence motifs and structures is limited20. 
Consequently, advanced approaches for scoring the functional effect of mutations, such as those used for protein 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7:41544 | DOI: 10.1038/srep41544
sequences, are unavailable. We have here hypothesised that driver lncRNAs should display an elevated mutational 
burden in their exons, under the assumption that function is mediated by the spliced transcript. Mutations in 
these regions might be presumed to affect function through disruption or creation of microRNA42 or protein 
binding sites43, or else through alterations to the RNA folding44,45. Future improvements to ExInAtor may include 
information on RNA structures, protein binding sites, post-transcriptional processing and evolutionary con-
servation to weight mutations based on their likely impact on lncRNA function. Furthermore, more sensitive 
statistical methods employing information on mutation clustering and cancer-specific mutational signatures will 
likely improve predictions.
It remains unclear how many lncRNA drivers remain to be discovered, and which have tumour-specific or 
pan-cancer activity. We expect that future studies will yield many more candidate lncRNAs than produced here: 
although the datasets we have used represent a large proportion of all presently available tumour genomes, future 
projects - including PCAWG - will be larger and produce mutation calls of better quality1,46. It is also likely that 
ExInAtor’s sensitivity can be improved in future: analyses of protein-coding and lncRNA true positive datasets 
clearly showed that, while ExInAtor makes predictions with high precision (high true positive rate), it likely also 
calls many false negatives. This lack of sensitivity arises from the fact that ExInAtor only uses mutational burden 
to call drivers, and ignores measures of functional impact. The benefit is ExInAtor’s agnosticism as to gene bio-
type, but it carries obvious drawbacks in sensitivity. For these reasons, it would be unwise at this point to com-
ment on the relative proportions of tumour-specific and pancancer lncRNAs. Nevertheless, evidence consistently 
points to lncRNA have a more tissue-specific expression compared to mRNAs4, making it plausible that they 
should have a higher rate of tumour-specificity compared to protein-coding genes.
The increasing scale of cancer genome projects will place a growing emphasis on computational efficiency. 
One of the benefits of ExInAtor is its ability to handle data with complex trinucleotide biases uses a simple sub-
sampling algorithm, and without any functional impact predictions. This simplicity has the unintended benefit 
that ExInAtor is capable of identifying protein-coding drivers with precision comparable to the best methods. 
Another outcome is that ExInAtor makes very low computational demands: analyses for this paper were executed 
on a workstation running Intel Core i7 processors. 25 minutes were required to analyse protein coding genes 
in Superpancancer (the largest dataset tested here) using a single core and 2,050 MB of RAM. It required just 
three minutes to analyse Pilocytic astrocytoma with six cores and 648 MB of RAM. Together, these features make 
ExInAtor suited to future, large-scale cancer genome sequencing projects.
Materials and Methods
Gene annotation and filtering. The GENCODE v19 lncRNA catalogue was downloaded in GTF format 
from (www.gencodegenes.org)4,47, and comprises 13,870 genes. A number of filtering steps were applied to this 
list. First, only intergenic genes (having no transcripts overlapping protein-coding genes on the opposite strand, 
or within 10 kb at their closest point on the same strand) were retained (6,308). Second, any lncRNA gene with 
transcripts of uncertain protein-coding potential were removed, leaving 5,887 genes (see below for details). Third, 
we included several cancer-related lncRNAs from the scientific literature, resulting in a final set of 5,914 lncRNA 
genes (Table 1 and Supplementary Files S1 and S2). Note that literature genes may violate the two filters above, but 
must have a GENCODE identifier. This set of filtered lncRNAs is used throughout.
The protein-coding gene catalogue was also obtained in GTF format from GENCODE v19 47. From this anno-
tation, all genes with biotype “protein-coding” were selected, resulting in 20,314 genes and 145,518 transcripts. 
Finally, all transcripts not having biotype “protein-coding” were removed, reducing the transcripts to 81,702. 
(Table 1 and Supplementary File S10).
Somatic mutation data curation. Whole-genome cancer somatic mutations were obtained in BED for-
mat from two sources: 10 cancers described in Alexandrov et al.21, and 14 cancers from TCGA1. In addition, we 
included an additional dataset of 100 stomach adenocarcinoma (STAD) with the Alexandrov dataset48, result-
ing in an original set of 22,877,059 mutations. Only single nucleotide somatic mutations and indels of length 
1 were retained, hereafter referred to as “mutations”. AML and ALL cancers from the Alexandrov dataset were 
removed due to their low number of genomes and mutations. Statistics on the remaining cancers can be found 
in Table 2. Both mutation datasets were prefiltered in order to remove possible misannotated germline SNPs. 
First, any mutations identical to an entry in dbSNP 146 “common” (> 1% frequency) were removed, leaving 
22,128,594 mutations (96.7%). Second, any recurrent mutations, having the same nucleotide change observed 
in the same location more than once, were collapsed and treated as a single event, resulting in a final set of 
20,837,263 mutations (91.1%). Other more stringent SNP filtering strategies resulted in a loss in precision and 
sensitivity (Supplementary File S12). We also experimented with removing hypermutated tumour samples, but 
once more this resulted in reduced performance (Supplementary File S12). A similar effect was observed after 
masking repetitive regions (Supplementary File S12).
Assessing the protein-coding potential of lncRNA. All GENCODE v19 lncRNA transcripts were 
tested for protein-coding potential with CPAT49 at default settings. Any gene having one or more transcripts 
predicted to be protein-coding (coding potential > = 0.364) was removed from further analysis.
ExInAtor design. ExInAtor requires eight mandatory inputs: (1) a gene annotation in GTF format contain-
ing information on genes and exons to analyse (transcript information is ignored), (2) a catalogue of mutations in 
BED format, (3) the number of individual genomes or samples represented by the BED file, (4) the output folder 
destination, (5) a file with two columns showing the name of each chromosome and its nucleotide length, (6) 
a gene annotation in GTF format containing information on genes and exons of the whole genome (transcript 
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information is ignored), (7) FASTA file of the whole genome and (8) a file containing all the possible trinucle-
otides. Optional inputs are: (1) a minimum number of exonic and/or (2) background mutations that each gene 
must have to be analysed, (3) the number of CPU cores to use in the analysis and (4) the extension length of the 
background region that includes all introns.
The ExInAtor workflow can be divided into the following steps: exon and background definition, mutations 
mapping, sub-sampling of background region, gene filtering by mutation counts and statistical analysis (Fig. 1 
and Supplementary Fig. S1).
Exon/Background definition. The full set of exons from all transcripts belonging to a gene are merged. The 
remaining genic space is then defined as background, which is extended to both sides of the gene according to the 
window length parameter. In the present study, this value was set at 10 kb throughout. Regions overlapping exons 
from any other gene are removed from this background region. The coordinates of non-overlapping exons and 
background regions are saved in BED format (Fig. 1A).
Mutations mapping. Mutations are mapped to exons and background regions, then counted. We collapsed the 
recurrent, identical mutations into one single mutation. However, if two or more distinct mutations fall in the 
same position they are counted separately.
Sub-sampling of background region. The trinucleotide content of the region is calculated. Then, an identical 
number of the same trinucleotides are randomly sampled from the background region. Their accompanying 
mutations are recorded. This is performed sequentially, without replacement, until it is impossible to continue. At 
every iteration, the sampled positions are added to a new background region, along with their associated muta-
tions. In this way, a new background region of maximal size and identical trinucleotide composition to the exonic 
region is assembled for every gene (Supplementary Fig. S1).
Gene filtering by mutation counts. Mutation data are sporadic and of low density, potentially resulting in inflated 
P values. To avoid this, ExInAtor accepts a user-defined minimum number of exonic and background mutations, 
below which lncRNAs will not be considered. These cutoffs may be defined by the user, with the default filter 
(used in the present study) discarding genes with less than 1 exonic mutations or 1 background mutations.
Statistical analysis. Statistical enrichment of exonic mutations is determined using the hypergeometric test 
(Fig. 1B). The following contingency table is compiled for each gene, with the total exonic and background 
lengths, N and n respectively:
M = number of exonic positions mutated
N − M = number of exonic positions not mutated
m = number of background positions mutated
n − m = number of background positions not mutated.
This is the starting point for calculations of statistical significance of enrichment of exonic mutations using 
the hypergeometric distribution, which describes the probability of obtaining a given number of successes in a 
given number of draws without replacement from a finite population of a specific size. It is important to note that 
the positions corresponding to each genome are counted independently, meaning that the total gene length N is 
defined as gene length multiplied by the number of genomes. n is treated similarly. Statistical significance is esti-
mated for a gene to have that many or more exonic mutations, then are corrected for multiple hypothesis testing 
using the Benjamini-Hochberg procedure, which controls the False Discovery Rate (FDR), here indicated by “Q”.
ExInAtor returns the input gene list with mutation counts and associated exonic enrichment Q-values. The 
latest ExInAtor version is freely available for download here: https://github.com/alanzos/ExInAtor/.
Creation of a simulated mutation dataset. Two distinct methods were used to create trinucleotide- 
aware simulations of tumour mutations. In the first method (“Fixed window reassignment”), the genome was 
divided into fixed partitions of 50 kb. Mutations were randomly assigned to another genomic location with the 
same reference trinucleotide and surrounding nucleotides for substitutions and indels, respectively. In the second 
method (“Sliding window reassignment”), a 50 kb window is centred on each individual mutation. The mutation 
is then reassigned to another position with identical reference trinucleotide within its window. These simulations, 
while maintaining approximately the same number of single nucleotide substitutions and indels of the original 
Alexandrov dataset as well as the same mutation trinucleotide signature, constitute neutral datasets that are not 
expected to be enriched in cancer related lncRNA.
Visual inspection and validation of candidates’ mutations. To verify the quality of the muta-
tion calling, we visually validated 12 single somatic mutations from 4 candidates. First, we downloaded 
a SAM file of the surrounding regions of each mutation (+ /− 2 kb) with the BAM Slicer tool from CGHUB 
(https://cghub.ucsc.edu/); then we opened those files with IGV to check the reads supporting the mutations 
(Supplementary Fig. S13)50.
Curation of Cancer Related LncRNA (CRL) set. A literature search was performed to identify lncRNAs 
with validated roles in cancer. Principal sources were Pubmed, lncRNAdb51 and lncRNADisease9. Two criteria 
were applied for inclusion. First, lncRNAs must have a GENCODE identifier. Second lncRNA must have a causa-
tive role in cancer or cancer-relevant phenotypes, as judged by in vitro or in vivo experiments, somatic mutations 
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or germline causative variants. Differential gene expression alone was not sufficient evidence for inclusion. The 
full set of CRL lncRNAs can be found in Supplementary File S1.
Comparison of cancer features. We obtained the list of lncRNA genes proximal to cancer-related 
germline SNPs from Table S5 of ref. 29. The enrichment of indicated lncRNA genesets with respect to these genes 
were assessed by contingency table analysis using Fisher’s Exact text. For the analysis of CNVs, the set of regions 
were obtained from Table S3 of the same paper, and statistical enrichments were calculated similarly. Only data 
from cancers corresponding to those in the present study were considered.
Comparison of lncRNA features. To assess which features may distinguish cancer lncRNAs, we collected 
different genomic and expression data for all the genes and divided them into the four groups of interest:
(1) non-CRL non-candidates (non-CRL gene list excluding ExInAtor discoveries at a Q ≤ 0.2, “All other 
lincRNAs”).
(2) CRL genes.
(3) all ExInAtor candidates (discovered at a Q ≤ 0.2).
(4) novel ExInAtor candidates (candidate genes that do not appear in the CRL list).
For each feature we compared all groups to non-CRL non-candidates. Statistical tests were performed using 
R. Features were compiled from the following sources:
Gene Sequence. Gene sequence features were calculated based on Gencode v19 annotations. Exonic regions of 
each gene were defined as the projection of all exons from the union of its transcripts. Promoter regions of each 
gene were defined as a window of + /− 100 nucleotides from the reference transcription start site (TSS).
Conservation. PhastCons scores from vertebrate and primate species alignments and PhastCons Elements 
from vertebrate, mammals and primate species alignments were downloaded from UCSC Genome Browser. Two 
separate analyses were performed, using either base-level scores, or conserved element regions. We separately 
computed the average exonic base-level conservation score of each gene for primates and vertebrates PhastCons 
scores. We merged conserved elements annotations from primate, mammal and vertebrate species alignments 
and intersected these regions with promoters and exonic regions. We then computed the percent of nucleotides 
(from promoters or exonic regions) covered by conserved elements for each gene.
Repeat Elements. We downloaded the 2013 version of RepeatMasker human genomic repetitive element anno-
tations and converted it to BED format. These annotations were intersected with exonic regions of lncRNAs. For 
each gene we calculated the percent of exonic nucleotides overlapping repetitive elements.
Tissue Expression Analysis. We extracted tissue expression values for 16 human tissues from Human Body Map 
(HBM) RNAseq data, downloaded from ArrayExpress under accession number E-MTAB-513. These data were 
used to quantify Gencode v19 genes using the GRAPE pipeline52. Considering only genes that are expressed 
(RPKM > 0) at least in one tissue we described the mean, the maximum and the variance of RPKM expression 
values across tissues. The percent of expressed genes for a given group represents the total number of genes that 
are expressed at least in one tissue compared to the total number of genes of the given group.
P53 analysis. We obtained ChIP data for p53 binding sites from ref. 28. Binding maps from the two available 
timepoints were merged. We attempted to assess a possible link between cancer driver lncRNAs and p53 binding 
site regions in two different ways. We first analysed whether the position of CRL genes in the genome tend to be 
closer to p53 binding site regions compared to non-CRL genes. To this aim, we calculated the nucleotide distance 
from the promoter of the gene (defined as explained before) to the closest p53 binding site region for all CRL and 
non-CRL genes. As an alternative, we compared the probability of finding a p53 binding site close to a TSS for 
CRL and non-CRL genes: for each we counted how many genes out of the total contain at least one predicted p53 
binding site region within a window of 100 kb, centred on the TSS.
Replication timing. Replication timing analysis was performed using data for the whole human genome pro-
duced by massively parallel sequencing of nascent BrdU-labeled replicating DNA in HeLa cells53. S50 ratios, 
defined as the fraction of the S phase at which 50% of the DNA is replicated in a defined genomic region, for 
100 kb genomic regions along the human genome were downloaded. These regions were intersected with 
ENCODE v18 long-noncoding RNA annotations, and the average of S50 values of the nucleotides of each gene 
was calculated.
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